Imricor Medical Systems, Inc.
Imricor Medical Systems, Inc. (IMR.AX) Financial Performance & Income Statement Overview
Review Imricor Medical Systems, Inc. (IMR.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Imricor Medical Systems, Inc. (IMR.AX) Income Statement & Financial Overview
Explore comprehensive income reports for Imricor Medical Systems, Inc. IMR.AX, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $551668.00 | $407756.00 | $208280.00 | $208280.00 |
| Cost of Revenue | $935688.00 | $947854.00 | $394953.00 | $394953.00 |
| Gross Profit | -$384020.00 | -$540098.00 | -$186673.00 | -$186673.00 |
| Gross Profit Ratio | -$0.70 | -$1.32 | -$0.90 | -$0.90 |
| R&D Expenses | $4.38M | $3.80M | $2.00M | $2.00M |
| SG&A Expenses | $3.47M | $3.72M | $1.68M | $1.68M |
| Operating Expenses | $7.85M | $7.52M | $3.68M | $6.52M |
| Total Costs & Expenses | $8.79M | $8.47M | $4.08M | $6.92M |
| Interest Income | $0.00 | $0.00 | $7702.00 | $7702.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $378639.00 | $369524.00 | $176435.00 | $176435.00 |
| EBITDA | -$7.86M | -$7.69M | -$3.69M | -$3.69M |
| EBITDA Ratio | -$14.24 | -$18.86 | -$17.72 | -$17.72 |
| Operating Income | -$8.24M | -$8.06M | -$3.87M | -$3.87M |
| Operating Income Ratio | -$14.93 | -$19.77 | -$18.57 | -$18.57 |
| Other Income/Expenses (Net) | -$14.60M | $1.20M | -$2.84M | -$2.84M |
| Income Before Tax | -$22.83M | -$6.86M | -$6.70M | -$6.70M |
| Income Before Tax Ratio | -$41.39 | -$16.82 | -$32.18 | -$32.18 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$22.83M | -$6.86M | -$6.70M | -$6.70M |
| Net Income Ratio | -$41.39 | -$16.82 | -$32.18 | -$32.18 |
| EPS | -$0.09 | -$0.04 | -$0.04 | -$0.04 |
| Diluted EPS | -$0.09 | -$0.04 | -$0.04 | -$0.04 |
| Weighted Avg Shares Outstanding | $257.33M | $190.67M | $161.75M | $161.75M |
| Weighted Avg Shares Outstanding (Diluted) | $257.33M | $190.67M | $161.75M | $161.75M |
Over the last four quarters, Imricor Medical Systems, Inc.'s revenue moved from $208280.00 in Q3 2023 to $551668.00 in Q4 2024. Operating income in Q4 2024 was -$8.24M, with a strong operating margin of -1493%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Imricor Medical Systems, Inc. remained robust at -$7.86M, reflecting operational efficiency. Net income dropped to -$22.83M, with an EPS of -$0.09. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan